SCHEDULE: Activist Investor Jorey Chernett Boosts Neuronetics Stake

Jorey Chernett has filed a Schedule 13D, disclosing a 14.12% beneficial ownership in Neuronetics, Inc., citing the shares as an undervalued investment opportunity.

Summary

• Jorey Chernett, a private investor, has filed a Schedule 13D, superseding his previous Schedule 13G, for Neuronetics, Inc. (the "Issuer").
• Chernett beneficially owns 9,778,718 shares of Neuronetics Common Stock, representing approximately 14.12% of the class outstanding as of March 10, 2026.
• The shares were acquired through private transactions using personal funds totaling $19,557,436.
• Chernett believes the shares were undervalued and represented an attractive investment opportunity when purchased.
• He may increase or decrease his position, engage with management and the Board, discuss potential business combinations or dispositions, and make recommendations regarding capitalization, ownership, board structure, or operational performance.
• Transactions in the past 60 days include both purchases and sales, with significant net purchases occurring in March 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant activist stake often signals potential for strategic changes and value realization, driven by an investor who believes the company is undervalued.

Positives

• A significant private investor, Jorey Chernett, has taken a substantial 14.12% stake in Neuronetics, Inc.
• The investor explicitly states a belief that the shares were "undervalued" and represented an "attractive investment opportunity."
• Potential for shareholder activism could lead to strategic changes aimed at improving shareholder value, such as business combinations, dispositions, or operational enhancements.

Negatives

• The filing itself does not present direct negatives about the company's performance.
• The presence of an activist investor, while potentially positive for value creation, can also signal dissatisfaction with current management or strategy, potentially leading to boardroom conflicts or uncertainty.

Risks

• The Reporting Person may endeavor to further increase or decrease his position, which could introduce volatility to the stock price.
• Potential for the Reporting Person to engage in discussions with stockholders or third parties about potential business combinations or dispositions involving the Issuer or certain of its businesses.
• The Reporting Person may make recommendations or proposals to the Issuer concerning changes to capitalization, ownership structure, board structure (including board composition), or suggestions for improving financial and/or operational performance, which could lead to management changes or strategic shifts.

Future Outlook

Jorey Chernett intends to review his investment in Neuronetics on a continuing basis. Depending on various factors, he may increase or decrease his position, engage in communications with management and the Board, discuss potential business combinations or dispositions, and make recommendations concerning capitalization, ownership structure, board composition, or operational performance.

Management Comments

• "The Reporting Person purchased the Shares based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity."
• "The Reporting Person may endeavor to further increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable."
• "The Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Issuer's Board of Directors, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance."

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13D by a significant individual investor like Jorey Chernett, particularly one who explicitly states a belief in undervaluation and an intent to engage with management, often signals the beginning of an activist campaign. This trend is common in sectors where companies may be perceived as underperforming relative to their assets or market potential, attracting investors seeking to unlock value through strategic or operational changes. Such filings can put pressure on existing management and boards to consider strategic alternatives or improve performance, aligning with broader industry trends of increased shareholder scrutiny and demand for accountability.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if Chernett's activism leads to positive strategic changes; potential for stock price volatility due to his buying/selling activity; increased scrutiny on management.
• Management/Board: Increased pressure to perform and potentially consider strategic alternatives; risk of conflict with the activist investor.
• Employees: Potential for strategic shifts (e.g., business combinations, dispositions) could impact employment, though not directly stated.

Next Steps

• Jorey Chernett will continue to review his investment in Neuronetics, Inc.
• He may increase or decrease his position in the Issuer.
• Potential engagement in additional communications with Neuronetics' management and Board of Directors.
• Possible discussions with other stockholders or third parties regarding Neuronetics' investment, including potential business combinations or dispositions.
• May make recommendations or proposals to Neuronetics concerning changes to capitalization, ownership structure, board structure, or operational performance.

Key Dates

Recommendation

A seasoned investor would likely place a 'hold' recommendation on Neuronetics shares following this Schedule 13D filing. While the activist investor's belief in undervaluation and potential for strategic engagement could be a positive catalyst for future value creation, the immediate impact and specific outcomes of such activism are uncertain. The filing itself does not provide new operational or financial performance data, but rather signals a potential shift in corporate governance dynamics. Investors would await further developments regarding Jorey Chernett's specific proposals and the company's response before making a more definitive 'buy' or 'sell' decision.

Keywords

Neuronetics, NEUR, Jorey Chernett, Schedule 13D, activist investor, beneficial ownership, undervalued stock, corporate governance, investment opportunity, stock purchase, shareholder activism